Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with select N3 lymph node involvement or other high-risk subsets in which there is no consensus on resectability. The main question it aims to answer is whether patients with stage 3 NSCLC with involvement of lymph nodes can undergo surgery to remove the cancer after receiving treatment with chemotherapy + immunotherapy. Participants will receive FDA-approved chemotherapy called platinum-doubl

Trial Details

NCT ID

NCT06449313

Phase

PHASE2

Sponsor

Georgetown University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Cemiplimab-Rwlc

Locations (sample)

Washington D.C., District of Columbia, United States|38.89511,-77.03637
St Louis, Missouri, United States|38.62727,-90.19789
Charlottesville, Virginia, United States|38.02931,-78.47668

Key Eligibility Criteria

Age ≥ 18 years at time of signing the informed consent form (ICF).
Histologically or cytologically confirmed stage 3 Non-Small Cell Lung Cancer (NSCLC) as assessed per the 8th American Joint Committee on Cancer (AJ…
Pathologically-confirmed contralateral mediastinal or ipsilateral supraclavicular (N3) lymph node involvement. Primary tumor and involved lymph nod…
Pathologically-confirmed T4N2 NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →